Serra Gürcan

Serra holds both a doctoral degree and a master’s in pharmaceutical technology. In 2015, Serra began her research journey at the University of Pavia, focusing on polymeric micelles to enhance the solubility of hydrophobic payloads. She then advanced to complete her doctoral research at the University of Paris Saclay in 2020, where she concentrated on developing a combined therapy utilizing cationic solid lipid nanoparticles complexed with anti-TNF alpha siRNA and an anti-inflammatory drug.
In 2021, she joined Cytiva (formerly known as Precision NanoSystems) as a Field Application Scientist in the Nanomedicine Unit, where she offered consultations on drug product production and lipid nanoparticles, particularly RNA-loaded LNPs. As of June 2024, Serra has taken on the role of Associate Director of Lipid and LNP Platform at CordenPharma, where she supports nanomedicine and lipid manufacturing services from a technical standpoint, both commercial and communication perspectives.